Amgen updates agreement with DaVita for dialysis treatment
Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →
Read More →Amgen sells Colorado facility to AstraZeneca for $64.5 million
Thousand Oaks biotech giant Amgen continued its Colorado exit plans recently as it sold a Longmont, Colo., facility to London-based pharmaceutical and biotech company AstraZeneca for $64.5 million. Amgen built the 692,000-square-foot facility in the 1990s to make ingredients for its blockbuster anti-anemia drug Epogen. The site used large vats to produce lines of cell Read More →
Read More →